Description
Anti-P-selectin glycoprotein ligand-1 Antibody, Non-Fucosylated (BioBet-1268ZP) is a humanized monoclonal IgG antibody against P-selectin glycoprotein ligand-1. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Autoimmune Diseases; Cancer; Psoriasis
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced P-selectin glycoprotein ligand-1 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
SELPLG
Full Name
selectin P ligand
Background
This gene encodes a glycoprotein that functions as a high affinity counter-receptor for the cell adhesion molecules P-, E- and L- selectin expressed on myeloid cells and stimulated T lymphocytes. As such, this protein plays a critical role in leukocyte trafficking during inflammation by tethering of leukocytes to activated platelets or endothelia expressing selectins. This protein requires two post-translational modifications, tyrosine sulfation and the addition of the sialyl Lewis x tetrasaccharide (sLex) to its O-linked glycans, for its high-affinity binding activity. Aberrant expression of this gene and polymorphisms in this gene are associated with defects in the innate and adaptive immune response. Alternate splicing results in multiple transcript variants.
Alternative Names
SELPLG; selectin P ligand; CLA; CD162; PSGL1; PSGL-1; P-selectin glycoprotein ligand 1; cutaneous lymphocyte-associated associated antigen
Gene ID
6404
Cellular Localization
Membrane
Involvement in Disease
Diseases associated with SELPLG include Human Granulocytic Anaplasmosis and Ehrlichiosis.
Related Pathways
Its related pathways are amb2 Integrin signaling and Cell surface interactions at the vascular wall.
Function
SLe(x) type proteoglycan, through high affinity, calcium-dependent interaction with E-, P- and l-selectin, mediates the rapid rolling of leukocytes on the surface of blood vessels in the initial stage of inflammation. It is essential for the initial white blood cell capture. (Microbial infection) As the recipient of Enterovirus 71.
Field of research
Cell Biology and Cellular Response antibody; Immune System antibody
Post-translational modifications
Displays complex, core-2, sialylated and fucosylated O-linked oligosaccharides, at least some of which appear to contain poly-N-acetyllactosamine with varying degrees of substitution. Mainly disialylated or neutral forms of the core-2 tetrasaccharide, Galbeta1-->4GlcNAcbeta1-->6(Galbeta1-->3)GalNAcOH. The GlcN:GalN ratio is approximately 2:1 and the Man:Fuc ratio 3:5. Contains about 14% fucose with alpha-1,3 linkage present in two forms: One species is a disialylated, monofucosylated glycan, and the other, a monosialylated, trifucosylated glycan with a polylactosamine backbone. The fucosylated forms carry the Lewis antigen and are important for interaction with selectins and for functioning in leukocyte rolling. The modification containing the sialyl Lewis X glycan is on Thr-57. No sulfated O-glycans. Some N-glycosylation. Sulfation, in conjunction with the SLe(x)-containing glycan, is necessary for P- and L-selectin binding. High affinity P-selectin binding has a preferred requirement for the isomer sulfated on both Tyr-48 and Tyr-51, whereas L-selectin binding requires predominantly sulfation on Tyr-51 with sulfation on Tyr-48 playing only a minor role. These sulfations play an important role in L- and P-selectin-mediated neutrophil recruitment, and leukocyte rolling.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
BioBet-1268ZP
Description
AbGn-168H is a humanized monoclonal antibody being developed to treat inflammatory diseases, has been demonstrated in a randomized, multicenter, double-blind, placebo-controlled phase II trial in patients with moderate-to-severe plaque psoriasis. Due to the unique mechanism of action, AbGn-168H has potential benefit for treating multiple immune-related diseases.
Antibody Indication
Autoimmune Diseases; Cancer; Psoriasis
Autoimmune Diseases; Cancer; Psoriasis
